Efficacy and safety of mild moxibustion in the treatment of diarrhea-predominant irritable bowel syndrome (spleen deficiency and dampness excess syndrome): A study protocol for a randomized controlled trial

ijiang Ji0 个研究点目标入组 92 人开始时间: 2023年5月23日最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Patients should meet both TCM and Western diagnostic criteria of IBS-D;
•2.Patients at age of 18 to 65 years old;
•3.No history of relevant treatment before enrollment or with discontinuation of treatment with Chinese medicine, antidiarrheal drugs and antispasmodics for more than 1 month;
•4.The total score of the IBS Severity Scoring System score(IBS-SSS) is more than 75;
•5.Voluntary participation in this study and signing of the informed consent form.

•1.Patients with IBS-C, IBS-M, and IBS-U;
•2.Patients with inflammatory bowel disease, organic intestinal lesions, peptic ulcer, infectious diarrhea;
•3.Patients combined with severe cardiovascular, hepatic, renal, endocrine and hematopoietic system diseases; patients with other diseases other than diarrhea that may affect the test results that cannot be discontinued; patients with mental illness;
•4.Patients who are pregnant or lactating, and those who have a birth plan from their enrollment to 1 month after the end of the trial;
•5.Those who have participated in other clinical trials within 1 month.

发起方

ijiang Ji